KPRX Insider Trading Activity and SEC Form 4 Filings
KPRX insider trading summary
No open-market insider purchases or sales of Kiora Pharmaceuticals Inc (KPRX) have been reported on SEC Form 4 in the past 12 months.
Latest KPRX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 11, 2024 | Carmine N. Stengone | Director | Buy | $5K (1,250 @ $3.68) |
| Sep 10, 2024 | Aron Shapiro | Director | Buy | $11K (3,000 @ $3.60) |
| Aug 19, 2024 | Praveen Tyle | Director | Buy | $20K (5,000 @ $3.96) |
| Aug 19, 2024 | Lisa Walters-Hoffert | Director | Buy | $5K (1,250 @ $3.86) |
| Aug 14, 2024 | Melissa Tosca | CFO | Buy | $6K (2,000 @ $3.21) |
| Jun 14, 2024 | Melissa Tosca | EVP Finance | Buy | $525 (100 @ $5.25) |
| Jun 14, 2024 | Eric Joseph Daniels | Chief Development Officer | Buy | $8K (1,431 @ $5.29) |
| Jun 13, 2024 | Erin Parsons | Director | Buy | $26K (5,260 @ $4.88) |
| Jun 13, 2024 | Brian M. Strem | President and CEO | Buy | $15K (3,000 @ $5.00) |
| Nov 18, 2021 | Brian M. Strem | President and CEO | Buy | $25K (17,853 @ $1.41) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.